| Zhang, Hong |
NCT03431428: Comparison of Short-term Efficacy and Long-term Prognosis for Reduction Surgery and Radical Resection in Almost-cCR Rectal Cancer Patients |
|
|
| Recruiting | 3 | 477 | RoW | transanal surgery, Miles surgery, Preoperative chemoradiotherapy | Zhang Rui | Almost-cCR, Surgery, Rectal Cancer | 01/20 | 12/22 | | |
| Completed | 3 | 1412 | RoW | Injection of recombinant human tissue plasminogen kinase derivatives, Reteplase, brand name: Ruitongli, r-PA, Recombinant human tissue plasminogen activator, Alteplase, brand name: Actilyse, rt-PA | Angde Biotech Pharmaceutical Co., Ltd., Beijing Tiantan Hospital | Acute Ischemic Stroke | 06/23 | 06/23 | | |
NCT05629390: Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study |
|
|
| Completed | 3 | 163 | RoW | Lotilaner, TP-03, S-Misoxam, Vehicle Control | LianBio LLC | Blepharitis | 09/23 | 04/24 | | |
NCT05745259: Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-Ⅲ） |
|
|
| Recruiting | 3 | 1630 | RoW | Alteplase, rt-PA, Tenecteplase, TNK-tPA | Beijing Tiantan Hospital, Jiangsu FENG HUA Biotech Pharmaceutical Co., Ltd, The Place Pharmaceutical(Jiangsu) Co., Ltd | Acute Ischemic Stroke | 11/23 | 03/24 | | |
TaLaR-02, NCT05984485: The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer |
|
|
| Recruiting | 3 | 766 | RoW | neoadjuvant chemotherapy plus total mesorectal excision, total mesorectal excision | Sun Yat-sen University | Rectal Cancer | 07/28 | 07/28 | | |
NCT05702489: A Study to Evaluate the Efficacy and Safety of ZX-7101A Tablets in Adults with Uncomplicated Influenza |
|
|
| Completed | 2/3 | 900 | RoW | ZX-7101A | Nanjing Zenshine Pharmaceuticals | Influenza, Human | 05/23 | 10/23 | | |
NCT04398459: The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia |
|
|
| Active, not recruiting | 2 | 18 | RoW | Ibrutinib, BTK inhibitor | Institute of Hematology & Blood Diseases Hospital, China | Refractory/Relapsed Autoimmune Hemolytic Anemia | 12/24 | 06/25 | | |
NCT05292196: A Phase II Clinical Trial of TQC3721 Suspension for Inhalation |
|
|
| Recruiting | 2 | 460 | RoW | TQC3721 suspension for inhalation, TQC3721 suspension placebo for inhalation | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Obstructive Pulmonary Disease (COPD) | 01/24 | 05/24 | | |
NCT06670352: Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN |
|
|
| Recruiting | 2 | 80 | RoW | Placebo, HSK39297 50mgBID, HSK39297 100mgBID, HSK39297 200mgQD | Haisco Pharmaceutical Group Co., Ltd. | IgA Nephropathy (IgAN) | 11/25 | 03/26 | | |
BID-PERAL, NCT04423367: Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment |
|
|
| Completed | 2 | 18 | RoW | bortezomib/dexamethasone | Institute of Hematology & Blood Diseases Hospital, China | Acquired Pure Red Cell Aplasia | 07/24 | 09/24 | | |
NCT05660785: Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia |
|
|
| Completed | 2 | 54 | RoW | Herombopag, Cyclosporine A | Institute of Hematology & Blood Diseases Hospital, China, Jiangsu Hengrui Pharmaceuticals Co.,Ltd | Non Severe Aplastic Anemia, Untreated | 01/25 | 01/25 | | |
NCT06687174: Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN) |
|
|
| Not yet recruiting | 2 | 72 | RoW | MY008211A tablets, MY008211A tablets matched placebo | Wuhan Createrna Science and Technology Co., Ltd | IgA Nephropathy (IgAN) | 06/26 | 01/28 | | |
NCT06760182: Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis |
|
|
| Not yet recruiting | 2 | 168 | RoW | TQH2722 injection, TQH2722 Placebo | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Seasonal Allergic Rhinitis | 06/25 | 08/25 | | |
NCT04688736: Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions. |
|
|
| Recruiting | 2 | 6642 | RoW | Placebo, Chlorpheniramine | Institute of Hematology & Blood Diseases Hospital, China | Allergic Transfusion Reaction | 12/25 | 06/26 | | |
NCT06774664: A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases |
|
|
| Not yet recruiting | 1/2 | 99 | RoW | SCTC21C | Sinocelltech Ltd. | IgA Nephropathy | 09/27 | 03/29 | | |
NCT04481841: Head Yuanshi Dian Therapy in Burning Mouth Syndrome |
|
|
| Recruiting | 1 | 290 | RoW | oryzanol + vitamin B2 (riboflavin) + vitamin E, head yuanshi dian therapy | Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Hospital of TCM, Guiyang Hospital of Stomatology | Burning Mouth Syndrome, Oral Mucosa Disease | 02/22 | 05/22 | | |
NCT06101316: A Bridging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB06-036 in Healthy Subjects in China |
|
|
| Recruiting | 1 | 12 | RoW | CB06-036 | Shanghai Zhimeng Biopharma, Inc. | Healthy Volunteers | 10/23 | 12/23 | | |
NCT06216041: To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects |
|
|
| Recruiting | 1 | 138 | RoW | IMM-H014, Placebo, IMM-H014 ( FE), Placebo ( FE) | Changchun Intellicrown Pharmaceutical Co. LTD | Nonalcoholic Steatohepatitis (NASH) | 07/24 | 12/24 | | |
NCT06160895: A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects |
|
|
| Completed | 1 | 40 | RoW | TQ-A3334 tablets, TQ-A3334 placebo tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatitis B | 06/24 | 08/24 | | |
NCT06427681: An Relative Bioavailability Study of BH006 for Injection in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 40 | NA | BH006 for injection, Fosaprepitant for injection+Palonosetron hydrochloride injection, EMEND®+PALONOSETRON | Zhuhai Beihai Biotech Co., Ltd | Bioavailability | 09/24 | 12/24 | | |
| Not yet recruiting | 1 | 18 | NA | AP303 150μg, AP303 300μg, Placebo 150μg, Placebo 300μg | Alebund Pharmaceuticals | Diabetic Kidney Disease | 01/25 | 01/25 | | |
| Completed | N/A | 980 | RoW | Rotational Atherectomy | Beijing Anzhen Hospital, BSC International Medical Trading (Shanghai) Co., Ltd. | Coronary Artery Disease | 12/20 | 01/22 | | |
UltraFuture I, NCT05498740: Post-marketing Study in Femoral Popliteal Artery of Drug Coated Balloon Used for Treatment of Lower Limb Ischemia |
|
|
| Recruiting | N/A | 200 | RoW | Drug eluting Balloon | Zhejiang Zylox Medical Device Co., Ltd. | Peripheral Arterial Disease (PAD) | 12/22 | 12/24 | | |
NCT05608980: 0.01% Hypochlorous Acid in the Treatment of Blepharitis |
|
|
| Recruiting | N/A | 100 | RoW | 0.01% hypochlorous acid, 0.01%HOCI, Placebo | Eye & ENT Hospital of Fudan University, ShuGuang Hospital | Blepharitis | 12/22 | 05/23 | | |
NCT05685966: Retrospective Study of COVID-19 on Reproductive Function |
|
|
| Recruiting | N/A | 400 | RoW | no intervention | Jinling Hospital, China | COVID-19 | 03/23 | 01/24 | | |
NCT04852406: Protocol-based Management and Perioperative Outcomes in Patients With Chronic Antithrombotic Therapy |
|
|
| Recruiting | N/A | 526 | RoW | Protocol-based management of perioperative antithrombotic therapy, Protocol-based management, Routine management of perioperative antithrombotic therapy, Routine management | Peking University First Hospital | Antithrombotic Therapy, Perioperative Care, Perioperative Outcomes | 12/23 | 01/24 | | |
NCT05685992: Novel Coronavirus Infection and Reproductive Function |
|
|
| Recruiting | N/A | 400 | RoW | no intervention | Jinling Hospital, China | COVID-19 Infection | 01/24 | 01/24 | | |
CSILS, NCT04527861: Oncologic Outcomes of Single-incision Versus Conventional Laparoscopic Surgery for Colorectal Cancer |
|
|
| Recruiting | N/A | 710 | RoW | Single-incision Laparoscopic Surgery, SILS, Conventional Laparoscopic Surgery, CLS | Ruijin Hospital, Dongfang Hospital Affiliated to Tongji University, Fudan University, Changhai Hospital, Shengjing Hospital, RenJi Hospital, Liaoning Cancer Hospital & Institute, Zhejiang Provincial People's Hospital, Shandong Provincial Hospital, The General Hospital of Western Theater Command, Shanghai Jiao Tong University School of Medicine | Colorectal Cancer, Colon Cancer, Rectal Cancer | 04/24 | 04/29 | | |
NCT04645810: A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence |
|
|
| Recruiting | N/A | 12 | US | High-Dose-Rate Brachytherapy | University of Rochester | Prostate Cancer, HDR | 05/26 | 05/27 | | |
SCDB, NCT06422845: Peripheral Scoring Drug-coated Balloon in the Treatment of Hemodialysis Arteriovenous Fistula Stenosis |
|
|
| Recruiting | N/A | 328 | RoW | Dissolve AV Peripheral Scoring Drug-coated Balloon, Scoring Drug-coated Balloon | DK Medical Technology (Suzhou) Co., Ltd. | Arteriovenous Fistula Stenosis | 07/27 | 07/27 | | |
| Recruiting | N/A | 1114 | RoW | TaTME, Transanal TME, LpTME, Laparoscopic TME | Sun Yat-sen University, Peking Union Medical College Hospital, The First Hospital of Jilin University, RenJi Hospital, Shengjing Hospital, The Second People's Hospital of Yibin, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Nanchong Central Hospital, Zunyi Medical College, The First Affiliated Hospital of University of South China, Xinqiao Hospital, Nanfang Hospital, Southern Medical University, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, Affiliated Hospital of Guangdong Medical University, The Third Xiangya Hospital of Central South University | Rectal Neoplasms Malignant, Surgery | 07/26 | 07/26 | | |
| Recruiting | N/A | 10000 | RoW | Installation or registration of smartphone application | Chinese Alliance Against Lung Cancer | Solitary Pulmonary Nodule | 10/25 | 10/25 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Not yet recruiting | N/A | 550 | RoW | lymph node dissection, Fluorescence-guided laparoscopic surgery, Radical operation for rectal cancer and sigmoid Cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Fudan University, Fujian Province Tumor Hospital, Guangdong Provincial People's Hospital, Shengjing Hospital, Affiliated Hospital of Qinghai University, Hebei Medical University Fourth Hospital, The Second Affiliated Hospital of Harbin Medical University, Jiangxi Provincial Cancer Hospital, The First Hospital of Jilin University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Shanxi Province Cancer Hospital, Nanfang Hospital, Southern Medical University, Second People's Hospital of Yunnan Province, Binzhou Medical University, The First Affiliated Hospital of University of Science and Technology of China, First Affiliated Hospital of Chengdu Medical College, The Second People's Hospital of Yibin, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Colorectal Neoplasms, Fluorescence, Lymph Node Excision | 12/26 | 06/27 | | |
| Recruiting | N/A | 366 | Canada, RoW | | The George Institute, Peking University Institute of Nephrology | IgA Nephropathy, ESRD, Glomerulonephritis, Kidney Diseases | 07/27 | 07/27 | | |
| Wang, Ying |
NCT05071482: Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL |
|
|
| Recruiting | 4 | 238 | RoW | Flumatinib, Imatinib | wang, jianxiang | Acute Leukemia | 10/25 | 10/25 | | |
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 |
|
|
| Recruiting | 3 | 366 | RoW | RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda | RemeGen Co., Ltd. | Breast Cancer | 06/24 | 12/24 | | |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 551 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | Type 2 Diabetes Mellitus | 03/25 | 12/25 | | |
MELATORCH, NCT03430297: A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma |
|
|
| Completed | 3 | 256 | RoW | JS001 240mg Q2W, Dacarbazine 1000mg/m2 Q3W | Shanghai Junshi Bioscience Co., Ltd. | Metastatic Melanoma, Unresectable Melanoma | 07/23 | 11/23 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
NCT06051409: A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL. |
|
|
| Recruiting | 3 | 350 | RoW | Olverembatinib, Imatinib | Ascentage Pharma Group Inc., HealthQuest Pharma Inc. | Ph+ ALL | 12/24 | 10/28 | | |
NCT06738979: A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects |
|
|
| Not yet recruiting | 3 | 408 | RoW | TQF3510 (Semaglutide Injection), Wegovy® | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Obesity | 07/26 | 08/26 | | |
DIAMOND, NCT04907370: PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 3 | 540 | RoW | PD-1 blocking antibody, PD-1 Blockade, Gemcitabine, GEM, Cisplatin (80mg/m2), DDP, Cisplatin (100mg/m2), Intensity-modulated radiotherapy, IMRT | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd. | Nasopharyngeal Carcinoma | 05/25 | 05/27 | | |
NCT05780372: Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 474 | RoW | Intensity Modulated Radiation Therapy, IMRT, Chemotherapy | Sun Yat-sen University, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, Chongqing University Cancer Hospital, Dongguan People's Hospital, LiuZhou People's Hospital | Nasopharyngeal Carcinoma, Radiotherapy; Complications | 05/25 | 05/28 | | |
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) |
|
|
| Recruiting | 3 | 756 | Europe, US, RoW | Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 07/27 | 07/29 | | |
NCT05904964: Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial) |
|
|
| Recruiting | 3 | 288 | RoW | Disitamab vedotin, RC48, Endocrine therapy | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | HR Positive/HER2 Low Expression Metastatic Breast Cancer | 03/28 | 03/30 | | |
NCT04646759: Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 516 | RoW | Fulvestrant combined with Pyrotinib, FASLODEX combined with Pyrotinib, Capecitabine combined with Pyrotinib, xeloda combined with Pyrotinib | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer | 12/28 | 12/30 | | |
NCT06083623: A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants |
|
|
| Not yet recruiting | 2b | 2250 | RoW | TNM001, placebo | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Respiratory Syncytial Virus Infections | 05/26 | 08/26 | | |
2019-KY-049, NCT04034589: Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer |
|
|
| Recruiting | 2 | 46 | RoW | Pyrotinib combined with fulvestrant | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Metastatic Breast Cancer | 07/21 | 07/22 | | |
NCT06429098: Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML |
|
|
| Recruiting | 2 | 40 | RoW | Venetoclax, ABT-199, ABT199, Venclexta, azacitidine, 5 AZC, 5-AZC, decitabine, Dacogen, Cytarabine, 1-.beta.-Cytosine arabinoside, Ara-C | The First Affiliated Hospital of Soochow University | Acute Myeloid Leukemia | 06/27 | 12/27 | | |
NCT04905550: Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC |
|
|
| Recruiting | 2 | 50 | RoW | Almonertinib, The third generation of EGFR - TKI, Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain Radiotherapy(WBRT) | Chongqing University Cancer Hospital | Non-Small Cell Lung Cancer (NSCLC) | 03/24 | 08/24 | | |
NCT05221658: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC |
|
|
| Recruiting | 2 | 60 | RoW | HLX07+HLX10+ Cisplatin+5-FU, HLX07 | Shanghai Henlius Biotech | ESCC or Esophageal Adenosquamous Carcinoma | 06/24 | 08/25 | | |
| Recruiting | 2 | 39 | RoW | Camrelizumab, Anti-PD-1 antibody, Stereotactic body radiotherapy, SBRT | Chongqing University Cancer Hospital | Nasopharyngeal Carcinoma | 08/24 | 08/26 | | |
| Recruiting | 2 | 22 | RoW | Anti-CD7 CAR-T | Ying Wang | Hematological Malignancies | 09/24 | 09/25 | | |
| Recruiting | 2 | 60 | RoW | Olverembatinib, Venetoclax, prednisone, Vincristine | Institute of Hematology & Blood Diseases Hospital, China | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | 10/24 | 03/25 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
NCT05660473: Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 2 | 100 | RoW | Vincristine, Daunorubicin, Cyclophosphamide, Pegaspargase, Prednisone, Cytarabine, 6-mercaptopurine, Dexamethasone, Methotrexate, Venetoclax | Institute of Hematology & Blood Diseases Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 12/24 | 12/27 | | |
NCT05213884: The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC |
|
|
| Recruiting | 2 | 30 | RoW | Camrelizumab, Anti-PD-1 antibody, Concurrent cisplatin chemotherapy, Intensity-modulated radiotherapy (IMRT) | Chongqing University Cancer Hospital | Head and Neck Squamous Cell Carcinoma | 01/25 | 01/27 | | |
NCT06059261: Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. |
|
|
| Recruiting | 2 | 45 | RoW | Envafolimab and recombinant human endostatin combined with chemoradiotherapy | Chongqing University Cancer Hospital, Fujian Cancer Hospital, Sun Yat-sen University | Nasopharyngeal Carcinoma | 10/27 | 10/27 | | |
NCT06776757: Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer |
|
|
| Recruiting | 1/2 | 30 | RoW | Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI) | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | Metastatic Colorectal Cancer | 06/25 | 12/25 | | |
| Recruiting | 1/2 | 203 | RoW | CN201, CN201 for Injection | Curon Biopharmaceutical (Shanghai) Co.,Ltd | Acute Lymphoblastic Leukemia | 05/25 | 07/25 | | |
NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors |
|
|
| Recruiting | 1/2 | 133 | RoW | KC1036 | Beijing Konruns Pharmaceutical Co., Ltd. | Digestive System Tumors | 10/25 | 12/25 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT06536400: Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation |
|
|
| Recruiting | 1 | 316 | RoW | HSK42360 | Haisco Pharmaceutical Group Co., Ltd. | Solid Tumors | 08/26 | 07/27 | | |
NCT06608329: A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 33 | RoW | HDM1002 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Healthy Adult Subject | 11/24 | 12/24 | | |
NCT05473624: Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 153 | RoW | HRS-1167 | Jiangsu HengRui Medicine Co., Ltd. | Advanced Solid Tumors | 12/24 | 12/24 | | |
NCT06725706: Beta Amyloid PET/CT in Various Aβ-Related Disease |
|
|
| Recruiting | N/A | 500 | RoW | 18F-92/AV45, 11C-PIB | Tianjin Medical University, Tianjin Medical University General Hospital | Amyloid, Beta-Amyloid, Neurodegenerative Diseases | 12/27 | 12/27 | | |
NCT06725719: Translocator Protein PET/CT in Various TSPO-Related Disease |
|
|
| Recruiting | N/A | 200 | RoW | 18F-DPA714/FDPA | Tianjin Medical University, Tianjin Medical University General Hospital | Neuroinflammation, Stroke, Neurodegenerative Diseases | 12/27 | 12/27 | | |
NCT05360043: Efficacy and Safety of 1565-nm Non-ablative Fractional Laser Versus Long-pulsed 1064-nm Nd:YAG Laser in the Treatment of Enlarged Facial Pores |
|
|
| Recruiting | N/A | 27 | RoW | laser treatment | Second Affiliated Hospital, School of Medicine, Zhejiang University | Enlarged Facial Pores | 04/22 | 10/22 | | |
NCT04800575: Comparison of Sterile Gauze and Semi-permeable Film Dressing for Hemodialysis Central Venous Catheter |
|
|
| Recruiting | N/A | 154 | RoW | semi-permeable film, sterile gauze and tape | Peking University People's Hospital | Infection, Bacterial | 05/22 | 12/22 | | |
NCT04008524: A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies |
|
|
| Available | N/A | | RoW | CAR-T cells | Institute of Hematology & Blood Diseases Hospital, Juventas Cell Therapy Ltd. | Relapsed and Refractory Hematological Malignancies | | | | |
HRQoL, NCT03926858: Patient-reported Outcomes of Postsurgical Pain and Health Related Quality of Life |
|
|
| Completed | N/A | 2000 | RoW | | Peking University People's Hospital | Post Surgical Pain | 05/23 | 05/23 | | |
| Recruiting | N/A | 100 | RoW | Prebiotic fructans, Non-prebiotic maltodextrin | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Beneo GmbH | Constipation | 12/22 | 12/22 | | |
NCT04880083: Feeding Tolerance and Gut Maturation of Infants Consuming a Formula Rich in Glycoprotein |
|
|
| Completed | N/A | 120 | RoW | Commercially Available Starter Infant Formula | Société des Produits Nestlé (SPN), Medrio, Inc, SAS Institute, Veeva Systems | Digestion, Gut Microbiota | 12/22 | 12/22 | | |
| Recruiting | N/A | 100 | RoW | Automated peritoneal dialysis, Intermittent hemodialysis | Limeng Chen, First Hospital of China Medical University, First Affiliated Hospital Xi'an Jiaotong University, Beijing Anzhen Hospital, Xiangya Hospital of Central South University, Baxter Healthcare Corporation | Acute Kidney Injury | 12/22 | 12/22 | | |
| Recruiting | N/A | 206 | RoW | automated peritoneal dialysis, IHD | Peking Union Medical College Hospital, First Hospital of China Medical University, Beijing Anzhen Hospital, The Luhe Teaching Hospital of the Capital Medical University, Ningbo No.2 Hospital | ESRD | 12/22 | 02/23 | | |
NCT05540795: Diagnostic Accuracy of 3T MR for Secondary Hyperparathyroidism Comparison With 4DCT |
|
|
| Completed | N/A | 15 | RoW | | Fifth Affiliated Hospital, Sun Yat-Sen University | Parathyroid Gland Disease, Secondary Hyperparathyroidism | 05/23 | 07/23 | | |
NCT06167109: NBI Combined With MRI to Guide CTV Optimization in Eccentric Nasopharyngeal Carcinoma |
|
|
| Recruiting | N/A | 60 | RoW | CTV optimized IMRT | Chongqing University Cancer Hospital | Nasopharyngeal Carcinoma by AJCC V8 Stage | 05/26 | 10/26 | | |
NCT05014893: Neural Mechanisms of Cognitive Assessment and Rehabilitation for Cognitive Decline |
|
|
| Recruiting | N/A | 100 | RoW | multi-modal targeted intervention (e.g., cognitive training, exercise, games) | National Research Center for Rehabilitation Technical Aids, Nanjing Brain Hospital, The Third People's Hospital of Yunnan Province, Central South University, Beijing academy of science and technology, Beijing University of Chinese Medicine | Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD), Aging, Healthy | 12/26 | 12/26 | | |
NCT06511453: Acupressure in Patients With Sickle Cell Disease |
|
|
| Recruiting | N/A | 240 | US | Acupressure (using AcuWand or pencil eraser) | Indiana University, University of California, Irvine | Sickle Cell Disease | 02/29 | 08/29 | | |
NCT05992285: A Clinical Study of Theta Burst Stimulation (cTBS) in the Treatment of Insomnia Disorder Targeting the Dentate Nucleus of the Cerebellum |
|
|
| Completed | N/A | 68 | RoW | transcranial magnetic stimulation | Xijing Hospital, First Affiliated Hospital of Xi'an Medical University, Xi'an No.1 Hospital, Xi'an International Medical Center Hospital, Xi'an Hospital of Traditional Chinese Medicine | Insomnia Disorder | 10/24 | 10/24 | | |
NCT05961566: Palatal Volumetric Change Analysis Following Connective Tissue Graft With and Without Donor Site Augmentation |
|
|
| Recruiting | N/A | 40 | US | Use of collagen matrix after subepithelial connective tissue graft harvest, Helistat - collagen matrix group, Experimental | Hailey Bivens | Recession, Gingival | 09/24 | 03/25 | | |
| Recruiting | N/A | 500 | RoW | 18F-S16/T807 | Tianjin Medical University, Tianjin Medical University General Hospital | Tauopathies, Neurodegenerative Diseases, Neurodegeneration | 11/27 | 12/27 | | |
NCT05483790: The Effects of Multidomain Non-pharmacological Interventions on the Elderly With or Without Mild Cognitive Impairment |
|
|
| Active, not recruiting | N/A | 112 | RoW | the multimodal intervention | Huashan Hospital, School of Public Health，Fudan University, Medicine-Mental Health Center of Minhang District, Xinzhuang Community Health Service Center | Mild Cognitive Impairment, The Cognitive Normal Elderly | 12/24 | 12/24 | | |
NCT06725550: Integrative Medicine in Pain Management in Sickle Cell Disease |
|
|
| Not yet recruiting | N/A | 120 | US | needling acupuncture, laser acupuncture | Indiana University | Sickle Cell Disease, Pain, Acupuncture, Quantitative Sensory Testing, Magnetic Resonance Imaging, Circulating Biomarkers, Electroencephalography, Functional Near-infrared Spectroscopy | 02/29 | 02/30 | | |
NCT05045820: Integrative Medicine in Pain Management in Sickle Cell Disease |
|
|
| Recruiting | N/A | 60 | US | needling acupuncture, laser acupuncture | Indiana University, National Center for Complementary and Integrative Health (NCCIH) | Sickle Cell Disease, Pain, Acupuncture, Quantitative Sensory Testing, Magnetic Resonance Imaging, Circulating Biomarkers, Electroencephalography, Functional Near-infrared Spectroscopy | 05/25 | 05/26 | | |
NCT04683757: The Establishment of a Survival Prediction Model for ER Positive / HER-2 Negative Advanced Breast Cancer |
|
|
| Recruiting | N/A | 288 | RoW | Establishment of a Survival Prediction Model | Ying Wang | Breast Cancer | 01/21 | 12/24 | | |
NCT04683445: Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer |
|
|
| Recruiting | N/A | 80 | RoW | Eribulin, Halaven, Trastuzumab, Herceptin, pertuzumab, Perjeta, Pyrotinib, Pembrolizumab, Keytruda, Camerlizumab | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer | 12/22 | 12/23 | | |
| Recruiting | N/A | 1000 | RoW | Carotid revascularization, carotid endarterectomy and carotid artery stent, MRI-PWI, CTA, PET/MRI, Ultrasound | Peking Union Medical College Hospital | Carotid Artery Stenosis | 12/25 | 12/26 | | |
| WANG, Ai'E |
| No trials found |
| ZHANG, Suiyang |
| No trials found |
| MA, Jianxin |
| No trials found |
| YAN, Chuanlian |
| No trials found |
| WANG, Dongxia |
| No trials found |
| LI, Chaoxia |
| No trials found |
